Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 205

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 205
---
Cash flow hedging activities, net of tax expense (benefit) of $16 in 2024, $(19) in 2023 and $5 in 202280 (84)— Other comprehensive income (loss)$380 $(106)$700 Comprehensive income4,666 4,767 12,545 Comprehensive income attributable to noncontrolling interest8 10 9 Comprehensive income attributable to AbbVie Inc.$4,658 $4,757 $12,536 

The accompanying notes are an integral part of these consolidated financial statements.

2024 Form 10-K   |  52

AbbVie Inc. and Subsidiaries

Consolidated Balance Sheets 

as of December 31 (in millions, except share data)20242023AssetsCurrent assetsCash and equivalents$5,524 $12,814 Short-term investments31 2 Accounts receivable, net10,919 11,155 Inventories4,181 4,099 Prepaid expenses and other4,927 4,932 Total current assets25,582 33,002 Investments279 304 Property and equipment, net5,134 4,989 Intangible assets, net60,068 55,610 Goodwill34,956 32,293 Other assets9,142 8,513 Total assets$135,161 $134,711 Liabilities and EquityCurrent liabilitiesCurrent portion of long-term debt and finance lease obligations$6,804 $7,191 Accounts payable and accrued liabilities31,945 30,650 Total current liabilities38,749 37,841 Long-term debt and finance lease obligations60,340 52,194 Deferred income taxes2,579 1,952 Other long-term liabilities30,129 32,327 Commitments and contingenciesStockholders' equity Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,831,594,494 shares issued as of December 31, 2024 and 1,823,046,087 as of December 31, 202318 18 Common stock held in treasury, at cost, 66,337,508 shares as of December 31, 2024 and 57,105,354 as of December 31, 2023(8,201)(6,533)Additional